<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="for antiviral therapy http://orcid.org/0000-0002-6380-7114BuonaguroLuigil.buonaguro@istitutotumori.na.it1TagliamonteMaria1TorneselloMaria Lina2BuonaguroFranco M.2[1], grid.417893.00000 0001 0807 2568Innovative" exact="Immunological" post="Models, Istituto Nazionale per lo Studio e la Cura"/>
 <result pre="Pascaleâ€�-IRCCS, [2], grid.417893.00000 0001 0807 2568Laboratory of Molecular Biology and" exact="Viral" post="Oncology, Istituto Nazionale per lo Studio e la Cura"/>
 <result pre="human coronavirus named SARS-CoV-2 was identified in several cases of" exact="acute" post="respiratory syndrome in Wuhan, China in December 2019. On"/>
 <result pre="coronavirus named SARS-CoV-2 was identified in several cases of acute" exact="respiratory" post="syndrome in Wuhan, China in December 2019. On March"/>
 <result pre="named SARS-CoV-2 was identified in several cases of acute respiratory" exact="syndrome" post="in Wuhan, China in December 2019. On March 11"/>
 <result pre="December 2019. On March 11 2020, WHO declared the SARS-CoV-2" exact="infection" post="to be a pandemic, based on the involvement of"/>
 <result pre="SARS-CoV-2 is a new human coronavirus identified in patients with" exact="acute" post="respiratory syndrome in Wuhan, China in December 2019 [1,"/>
 <result pre="is a new human coronavirus identified in patients with acute" exact="respiratory" post="syndrome in Wuhan, China in December 2019 [1, 2]."/>
 <result pre="a new human coronavirus identified in patients with acute respiratory" exact="syndrome" post="in Wuhan, China in December 2019 [1, 2]. Since"/>
 <result pre="China in December 2019 [1, 2]. Since then, the SARS-CoV-2" exact="infection" post="has become a pandemic, reaching almost every Country in"/>
 <result pre="CoV emerged in the past 20Â years, namely the severe" exact="acute" post="respiratory syndrome CoV (SARS-CoV) and the Middle East respiratory"/>
 <result pre="emerged in the past 20Â years, namely the severe acute" exact="respiratory" post="syndrome CoV (SARS-CoV) and the Middle East respiratory syndrome"/>
 <result pre="in the past 20Â years, namely the severe acute respiratory" exact="syndrome" post="CoV (SARS-CoV) and the Middle East respiratory syndrome CoV"/>
 <result pre="severe acute respiratory syndrome CoV (SARS-CoV) and the Middle East" exact="respiratory" post="syndrome CoV (MERS-CoV) [3], also the current SARS-CoV-2 is"/>
 <result pre="acute respiratory syndrome CoV (SARS-CoV) and the Middle East respiratory" exact="syndrome" post="CoV (MERS-CoV) [3], also the current SARS-CoV-2 is suggested"/>
 <result pre="additional SARS-like and MERS-like coronaviruses able to replicate efficiently in" exact="primary" post="human lung cells [5]. It is therefore predictable that"/>
 <result pre="reaching the new host through coughing and sneezing, both in" exact="symptomatic" post="and asymptomatic positive subjects [6, 7]. Moreover, active virus"/>
 <result pre="positive subjects [6, 7]. Moreover, active virus replication in the" exact="upper" post="respiratory tract is observed in patients also after the"/>
 <result pre="subjects [6, 7]. Moreover, active virus replication in the upper" exact="respiratory" post="tract is observed in patients also after the peak"/>
 <result pre="tract is observed in patients also after the peak of" exact="respiratory" post="symptoms, which may result in prolonged viral spreading of"/>
 <result pre="the peak of respiratory symptoms, which may result in prolonged" exact="viral" post="spreading of the infection [8]. Therefore, reducing the viral"/>
 <result pre="symptoms, which may result in prolonged viral spreading of the" exact="infection" post="[8]. Therefore, reducing the viral titer represents a major"/>
 <result pre="prolonged viral spreading of the infection [8]. Therefore, reducing the" exact="viral" post="titer represents a major goal in order to slow/block"/>
 <result pre="titer represents a major goal in order to slow/block the" exact="disease" post="progression as well as to significantly limit the viral"/>
 <result pre="the disease progression as well as to significantly limit the" exact="viral" post="shedding. The latter objective would result in the lowering"/>
 <result pre="coronaviruses SARS-CoV and MERS-CoV. Similarly to all RNA viruses, the" exact="viral" post="genome replication and transcription processes of SARS-CoV-2 depend on"/>
 <result pre="RNA templates. Consequently, RdRp is the key enzyme in the" exact="viral" post="biological cycle of all RNA viruses, regardless the polarity"/>
 <result pre="cycle of all RNA viruses, regardless the polarity of the" exact="viral" post="RNA genome [9, 10]. Although different for each RNA"/>
 <result pre="genome [9, 10]. Although different for each RNA viruses, all" exact="viral" post="RdRps are characterized by a 500â€&quot;600 residue catalytic module"/>
 <result pre="(Motif C) is the most conserved region of all monomeric" exact="viral" post="RNA polymerases with two aspartic acid residues that coordinate"/>
 <result pre="[14]. Mutation of the first aspartic residue results in a" exact="complete" post="loss of RNA polymerase activity, whereas mutations of the"/>
 <result pre="acid in Motif C which has been shown to enable" exact="viral" post="RNA polymerases to use manganese (Mn2+) instead of magnesium"/>
 <result pre="RNA virus, namely HCV, Dengue, West Nile, Zika and Yellow" exact="Fever" post="viruses (Fig.Â 1b). In particular, HCV shows the greatest"/>
 <result pre="of positive-sense viruses HCV, Dengue, West Nile, Zika and Yellow" exact="Fever" post="viruses; c Sequences from positive-sense coronaviruses and negative-sense viruses"/>
 <result pre="from positive-sense coronaviruses and negative-sense viruses Influenza, Ebola, Rabies, Vesicular" exact="Stomatitis" post="virus, Measle, LCMV, Respirovirus and Orthopneumovirus. Red dots indicate"/>
 <result pre="aligned with negative-sense RNA viruses, namely Ebola, Influenza, Rabies, Vesicular" exact="Stomatitis" post="virus, Measle, LCMV, Respirovirus and Orthopneumovirus (Fig.Â 1c). As"/>
 <result pre="molecules which are in direct contact with the target genomic" exact="viral" post="RNA and are responsible of the elongation of the"/>
 <result pre="developed to target the RdRp regions directly involved in the" exact="viral" post="genome replication and transcription. Nucleoside analogs would be the"/>
 <result pre="to be effective for other positive-sense RNA viruses, namely Yellow" exact="Fever" post="and Hepatitis A virus [23, 24]. In conclusion, as"/>
 <result pre="effective for other positive-sense RNA viruses, namely Yellow Fever and" exact="Hepatitis" post="A virus [23, 24]. In conclusion, as for all"/>
 <result pre="virus represents the most optimal target for an antiviral drug." exact="Linear" post="amino acid sequence as well as molecule structure show"/>
 <result pre="novel coronavirus in salivaClin Infect Dis202010.1093/cid/ciaa14932318718 7.RotheCSchunkMSothmannPBretzelGFroeschlGWallrauchCet al.Transmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in GermanyN Engl J Med202038297097110.1056/NEJMc200146832003551"/>
 <result pre="among RNA-dependent RNA polymerasesCurr Top Microbiol Immunol200832013715618268843 15.LohmannVKornerFHerianUBartenschlagerRBiochemical properties of" exact="hepatitis C" post="virus NS5B RNA-dependent RNA polymerase and identification of amino"/>
 <result pre="in rhesus monkeysNature201653138138510.1038/nature1718026934220 19.FurutaYKomenoTNakamuraTFavipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProc Jpn Acad Ser B Phys Biol Sci20179344946310.2183/pjab.93.027"/>
 <result pre="al.An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway" exact="epithelial" post="cell cultures and multiple coronaviruses in miceSci Transl Med202010.1126/scitranslmed.abb588332253226"/>
 <result pre="coronaviruses in miceSci Transl Med202010.1126/scitranslmed.abb588332253226 23.MendesEAPilgerDRBSantos NastriACSMaltaFMPascoalinoBDSCarneiro Dâ€™AlbuquerqueLAet al.Sofosbuvir inhibits" exact="yellow fever" post="virus in vitro and in patients with acute liver"/>
 <result pre="inhibits yellow fever virus in vitro and in patients with" exact="acute" post="liver failureAnn Hepatol20191881682410.1016/j.aohep.2019.09.00131594756 24.JiangWMuhammadFMaPLiuXLongGSofosbuvir inhibits hepatitis A virus replication"/>
 <result pre="and in patients with acute liver failureAnn Hepatol20191881682410.1016/j.aohep.2019.09.00131594756 24.JiangWMuhammadFMaPLiuXLongGSofosbuvir inhibits" exact="hepatitis" post="A virus replication in vitro assessed by a cell-based"/>
</results>
